- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01585818
Dietary Intervention in Diabetes Mellitus (DIDM)- Intermediate and Acute Effects (DIDM)
Nutrition Studies and Dietary Intervention in Individuals With Type 2 Diabetes Mellitus of Chinese, Malay and Indian Ethnicity
Lifestyle modification, in particular adopting an appropriate dietary pattern, is generally accepted as the cornerstone for the treatment of people with type 2 diabetes mellitus (T2DM). Consumption of low glycaemic index (GI) meals have been shown to improve glycaemic control, lipid profile and reduced systemic inflammation. However, these studies and international evidence-based nutritional recommendations are principally based on people of European ethnicity consuming fairly typical "western" diets. There are few published controlled dietary intervention studies which have attempted to determine appropriate dietary patterns for the treatment of diabetes amongst populations consuming rice-based diets.
HYPOTHESIS
- The glycaemic response over 6 days as measured by CGMS will have a lower mean glucose level and postprandial increase in individuals consuming the LGI compared with the SDI meal plan.
- A LGI meal plan is acceptable and participants will adhere and comply to the diet to the same level as those receiving the SDI meal plan.
- Glycaemic and metabolic parameters as measured by integrated area under the curve (IAUC) of glucose and insulin are lower after a single meal comprising of LGI than compared with an SDI meal.
- The effect of a single meal of LGI reduces appetite and increases satiety compared with a meal of SDI.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study builds on the information collected from phase 1 which involved the documentation of clinical and metabolic characteristics and dietary practices of Chinese individuals with T2DM. In addition to information from a separate study on GI testing of locally consumed carbohydrate containing foods, we have formulated a meal plan comprising of low GI carbohydrates. Participants will be randomised into the low GI (LGI) intervention arm or standard dietary intervention (SDI) arm and receive counselling and advice from a dietitian, embark on a two week protocol to test the recommended diet, be reviewed by the dietitian, and undergo a 3 to 6 day continuous glucose monitoring period before and after the LGI or SDI diet. In addition, they will undergo 2 separate single day test meals comprising of low GI and high GI foods. Participants in both groups will be given resources including detailed instructions and meal plans that are comparable between the two arms in terms of contact with research personnel, instructions and meal plans which are isocaloric and have similar macronutrient composition appropriate for their energy requirements.
Participants will be advised to continue on the meal plans and diet for a further 22 weeks. At the second month, a telephone call will be made to the participant to review compliance. At month 3 and month 6, participants will be asked to attend after an overnight fast from 10pm, for a blood sample, return a food diary/ recall, measurement of anthropometry and blood pressure. In addition, they will complete a questionnaire
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Eric YH Khoo, MD
- Phone Number: 67724352
- Email: eric_khoo@nuhs.edu.sg
Study Locations
-
-
-
Singapore, Singapore, 119228
- Recruiting
- National University Hospital
-
Contact:
- Eric YH Khoo, MD
- Phone Number: 67724352
- Email: eric_khoo@nuhs.edu.sg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be willing and able to comply with study procedures and give written informed consent
- Have established diagnosis of type 2 diabetes* of more than 1 year on diet treatment or oral anti-diabetic therapy
- Male or female, aged 45 to 64 years inclusive
- HbA1c of 7.0 - 10.0% (inclusive) within the last 3 months or at screening
- Stable glycaemic control
- Patients with concurrent illnesses if medically stable for 6 months prior to screening visit, based on the clinical judgement of the investigator
- Be on stable therapy (no significant change to therapy in last 3 months)
- No hospitalization or surgery in the past 6 months
- No use of corticosteroids in the last 6 months
- Not pregnant
- Urea <30 mmol/L and estimated GFR >= 60ml/min
- Be willing to prepare and adhere to the meal plans and consume at least two meals at home per day.
Be willing and able to undertake blood glucose monitoring, continuous glucose monitoring.
- Subjects with Type 2 DM should have been diagnosed at least 1 years prior to the screening visit and should not have T1DM, MODY or secondary diabetes e.g. diabetes secondary to chronic pancreatitis
Exclusion Criteria:
- Significant medical conditions which in the Investigator's opinion would confound interpretation of the results, including but not limited to: current symptomatic cardiovascular disease, macroalbuminuria (dipstick positive proteinuria on more than 1 consecutive occasion) or renal impairment (serum creatinine above 120 umol/l), cancer, overt liver disease other than Non Alcoholic Steatohepatitis (liver enzyme levels less than 3 times upper limit of normal) or gastroparesis.
- Recent changes in weight of >5% over the past 6 months
- Significant changes in diet over the past 6 months
- Any use of weight reducing drugs, or on medications such as alpha-glucosidase inhibitors or insulin currently or in the past 6 months
- Any surgery (and bariatric surgery) in the past 6 months
- Any use of investigational drugs in the past 6 months
- Any serious illness requiring hospitalization in the past 6 months
- Any use of corticosteroids in the past 6 months
- Ongoing infection, or condition that interfered with nutrient digestion, absorption, metabolism or excretion (including gastroparesis)
- Allergy or intolerant to the ingredients or any of the food items in the intervention diet or to paracetamol/ acetaminophen
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: standard dietary intervention (SDI) arm
The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre
|
The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre.
Participants will be provided with a list of carbohydrates to take during the intervention period and will be provided a supply of carbohydrates for that period
Other Names:
|
Experimental: LGI intervention arm
The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes.
Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.
Participants will be provided with a list of low GI carbohydrates to consume during the intervention period and in addition, they will be provided with a supply of the staples for the same period
|
The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes.
Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average mean glucose levels and variability
Time Frame: 2 weeks
|
To assess the intermediate effects on glycaemia and metabolic response to a meal plan comprising of LGI compared with a SDI meal plan
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HBA1C
Time Frame: 3 and 6 months
|
|
3 and 6 months
|
Glucose and Insulin Levels
Time Frame: 1 week
|
To assess glycemic and metabolic response to a mixed meal
|
1 week
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Eric YH Khoo, MD, National University Hospital / Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SICS-10/1/2/002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Standard Diet Intervention
-
University of PecsRecruitingAcute PancreatitisHungary
-
Stanford UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingObesity | Diabetes Mellitus, Type 2 | Insulin Resistance | PreDiabetes | Diet Modification | Nonalcoholic Steatohepatitis | Nonalcoholic Fatty LiverUnited States
-
Tel-Aviv Sourasky Medical CenterNutricia LiverpoolUnknown
-
Nemours Children's ClinicCompleted
-
Eunice Kennedy Shriver National Institute of Child...CompletedType 1 Diabetes | Type 2 Diabetes | Impaired Glucose Metabolism
-
University of Texas at AustinNational Cattlemen's Beef AssociationRecruitingEating Behavior | Breast Feeding, Exclusive | Glycemic ResponseUnited States
-
Ohio State UniversityRecruiting
-
University College CorkCompleted
-
University of GuadalajaraCompletedObesity | Inflammatory Response | Exercise | Diet Habit | Abdominal ObesityMexico
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruiting